uPA-uPAR系统在动脉粥样硬化发生发展中的作用  

Roles of uPA-uPAR System in the Development of Atherosclerosis

作　　者：高鑫宇 彭瑜[1] 张钲[1] GAO Xin-yu;PENG yu;ZHANG zheng.(Department of Cardiology, the first hospital of Lanzhou universty. 730000, Lanzhou, China)

机构地区：[1]兰州大学第一医院心血管内科,兰州市730000

出　　处：《中国分子心脏病学杂志》2018年第1期2390-2392,共3页Molecular Cardiology of China

基　　金：甘肃省心血管疾病重点实验室(NO:1206RTSA025)

摘　　要：尿激酶纤溶酶原激活物(u PA)-尿激酶纤溶酶原激活物受体(u PAR)系统在动脉粥样硬化发生发展中起重要作用。尿激酶纤溶酶原激活物(u PA)及u PA介导的S100A12/RAGE分别通过介导单核细胞源性泡沫细胞及平滑肌源性泡沫细胞的形成,促进动脉粥样硬化的发生发展,其中S100A12/RAGE有望成为新型抗动脉粥样硬化药物作用靶点。尿激酶纤溶酶原激活物受体(u PAR)裂解生成的su PAR与冠状动脉粥样硬化病变严重程度呈正相关,并可以预测冠心病患者发生不良心血管事件发生的可能性。本文主要从以上两个方面分别介绍u PA-u PAR系统在动脉粥样硬化发生发展中的作用。Urokinase plasminogen activator（uPA）-urokinase plasminogen activator receptor（uPAR） system plays an important role in the progression of atherosclerosis. Urokinase plasminogen activator（uPA） and uPA-mediated S100 A12/RAGE promote the development of atherosclerosis by mediating monocyte-derived foam cells and smooth muscle-derived foam cells respectively. In which S100 A12/RAGE is expected to be a new target for anti-atherosclerotic drugs. suPAR is the cleavage form of urogenase plasminogen activator receptor（uPAR） which not only positively correlated with coronary atherosclerotic lesions severity, but also can predict the possibility of adverse cardiovascular events in patients with coronary heart disease. In this review, we mainly introduce the function of uPA-uPAR system in the development of atherosclerosis from the above two aspects.

关 键 词：动脉粥样硬化 尿激酶纤溶酶原激活物 S100A12蛋白 晚期糖化终产物受体 可溶性尿激酶纤溶酶原激活物受体 

分 类 号：R543.5[医药卫生—心血管疾病]